Evidence map›Paper›PMID 33476239›Full record

ArticleAmerican journal of public health2021

The Costs of Contradictory Messages About Live Vaccines in Pregnancy.

Elana Jaffe, Ilona Telefus Goldfarb, Anne Drapkin Lyerly

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Elana JaffeElana Jaffe is with the Center for Bioethics, Department of Social Medicine, School of Medicine, and the Department of Maternal, Child, and Family Health, Gillings School of Global Public Health, University of North Carolina, Chapel Hill. Ilona Telefus Goldfarb is with the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA. Anne Drapkin Lyerly is with the Center for Bioethics, Department of Social Medicine, and the Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina, Chapel Hill.
Ilona Telefus GoldfarbElana Jaffe is with the Center for Bioethics, Department of Social Medicine, School of Medicine, and the Department of Maternal, Child, and Family Health, Gillings School of Global Public Health, University of North Carolina, Chapel Hill. Ilona Telefus Goldfarb is with the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA. Anne Drapkin Lyerly is with the Center for Bioethics, Department of Social Medicine, and the Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina, Chapel Hill.
Anne Drapkin LyerlyElana Jaffe is with the Center for Bioethics, Department of Social Medicine, School of Medicine, and the Department of Maternal, Child, and Family Health, Gillings School of Global Public Health, University of North Carolina, Chapel Hill. Ilona Telefus Goldfarb is with the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA. Anne Drapkin Lyerly is with the Center for Bioethics, Department of Social Medicine, and the Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina, Chapel Hill.

Funding

The PHASES Project: Pregnancy and HIV/AIDS-Seeking Equitable StudyR01AI108368 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAY, SUZANNE LOUISE, LYERLY, ANNE DRAPKIN · 2015 to 2024
$6.4M
Integrating Decision Making Studies into HIV Cure Trials: A real-time longitudinal assessmentR01AI127024 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HENDERSON, GAIL E · 2016 to 2019
$2.2M
NIAID NIH HHS R01 AI108368NIAID NIH HHS R01 AI127024
6 · The paper itself

Abstract

The increased risk of harm from COVID-19 infection in pregnancy highlights the importance of including pregnant people in COVID-19 vaccine development and deployment. Promising vaccines being developed include replication-competent platforms, which are typically contraindicated during pregnancy because of theoretical risk. However, replicating vaccines are administered in and around pregnancy, either inadvertently because of unknown pregnancy status or when recommended.The historical cases of Ebola virus, yellow fever, and rubella demonstrate that contradictory messages around the safety of live vaccines in pregnancy have critical public health costs. First, restricting study or use of replicating vaccines in pregnancy may delay or deny access to the only available protection against deadly diseases. Additionally, not vaccinating pregnant people may slow epidemic control. Finally, uncertainty and worry around the safety of live vaccines may lead to terminations of otherwise desired pregnancies after inadvertent vaccination in pregnancy.If one of the vaccines deployed to combat the current global COVID-19 pandemic is replication competent, historical cases offer important lessons for ethical and effective protection for pregnant populations.

Indexed as

COVID-19COVID-19 VaccinesDrug DevelopmentFemaleHumansPandemicsPregnancyPregnancy Complications, InfectiousPregnant PeopleSARS-CoV-2Vaccines, Live, UnattenuatedCOVID-19 VaccinesVaccines, Live, Unattenuated

Identifiers

PMID33476239
PMCPMC7893372

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.